Plain-English translation of NCT06594926 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment approach for men with castrate-resistant prostate cancer—cancer that no longer responds to standard hormone-lowering therapy—but has not yet spread to distant parts of the body. The study combines testosterone enthanate (given as injections in cycles) with darolutamide (a daily medication you may already be taking). The goal is to see if this combination can slow or delay the cancer's progression.
Right now, when prostate cancer stops responding to standard treatments but hasn't spread yet, doctors have limited options. This trial explores whether giving testosterone in a controlled, cyclical way—alongside the medication you're already on—could help keep the cancer from spreading and give patients more time before needing stronger treatments.
You likely qualify if…
You likely don't qualify if…
You would receive testosterone injections on a set schedule (every 56 days), while continuing your regular darolutamide tablets and hormone therapy. Throughout the trial, you'll have blood tests drawn regularly, complete questionnaires about how you're feeling, and have imaging scans done to check if the cancer is progressing. The treatment continues in these 56-day cycles until scans show the cancer has spread to distant sites, unless you and your doctor decide to continue beyond that point.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Australia